Kyung Bo Kim
- Oncology top 5%
- Peptidase Inhibition and Analysis 22
- Molecular Biology top 5%
- Ubiquitin and proteasome pathways 30
- Protein Degradation and Inhibitors 14
- Glycosylation and Glycoproteins Research 4
- Hematology top 5%
- Multiple Myeloma Research and Treatments 10
- Cell Biology top 5%
-
- Alzheimer's disease research and treatments 5
-
- interferon and immune responses 4
-
- HIV/AIDS drug development and treatment 4
- Co-authors
- Craig M. CrewsJayhyuk MyungWooin LeeZachary MillerNorman KairiesM. GrollRobert HuberNy Sin
- Cited by
- OncologyMolecular BiologyHematology
- Partner nations
- United StatesSouth KoreaGermany
In The Last Decade
Kyung Bo Kim
60 papers receiving 2.5k citations
Peers
Comparison fields: 5 of 127
- Oncology 769
- Molecular Biology 1.8k
- Hematology 265
- Cell Biology 272
- Complementary and alternative medicine 134
Countries citing papers authored by Kyung Bo Kim
This map shows the geographic impact of Kyung Bo Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyung Bo Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyung Bo Kim more than expected).
Fields of papers citing papers by Kyung Bo Kim
This network shows the impact of papers produced by Kyung Bo Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyung Bo Kim. The network helps show where Kyung Bo Kim may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Kyung Bo Kim, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2022 | 4 | |
| 3 | 2021 | 6 | |
| 4 | 2021 | 11 | |
| 5 | 2021 | 6 | |
| 6 | 2020 | 12 | |
| 7 | 2019 | 12 | |
| 8 | 2019 | 22 | |
| 9 | 2018 | 110 | |
| 10 | 2017 | 33 | |
| 11 | 2013 | 21 | |
| 12 | 2012 | 26 | |
| 13 | Implications and Development of AHR-based Therapeutic Agents | 2012 | 2 |
| 14 | 2011 | 39 | |
| 15 | 2011 | 19 | |
| 16 | 2011 | 52 | |
| 17 | 2010 | 11 | |
| 18 | 2008 | 5 | |
| 19 | 2001 | 103 | |
| 20 | 2000 | 88 |
About Kyung Bo Kim
Kyung Bo Kim is a scholar working on Hematology, Oncology and Molecular Biology, having authored 61 papers that have together received 2.6k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (30 papers), Peptidase Inhibition and Analysis (22 papers), Protein Degradation and Inhibitors (14 papers), Multiple Myeloma Research and Treatments (10 papers), Alzheimer's disease research and treatments (5 papers), Glycosylation and Glycoproteins Research (4 papers), interferon and immune responses (4 papers) and HIV/AIDS drug development and treatment (4 papers). The work is most often cited by research in Oncology (769 citations), Molecular Biology (1.8k citations) and Hematology (265 citations). Kyung Bo Kim has collaborated with scholars based in United States, South Korea and Germany. Frequent co-authors include Craig M. Crews, Jayhyuk Myung, Wooin Lee, Zachary Miller, Norman Kairies, M. Groll, Robert Huber, Ny Sin, Ji Eun Park and Chang‐Guo Zhan.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.